abstract |
The invention relates to a parenterally administrable, liposomal dihydropyridine formulation based on liposomes with a phospholipid membrane, the active ingredient / phospholipid ratio being between 1:20 and 1: 100 and the average liposome diameter being between 40 and 200 nm and having a pH after reconstitution -Value between 4.5 and 6.5, and a process for their preparation. |